Skip to main content
. 1999 Jun 8;96(12):7023–7028. doi: 10.1073/pnas.96.12.7023

Table 1.

Effects of CE on BAS–CA1 PSPs of CA1 pyramidal cells

Treatment n % PSPs
Reversal potential, mV
Control Test P Control Test P
CE 10 −101.1  ±  4.2 −49.9  ±  4.7∗ −79.0  ±  1.0 −70.1  ±  1.4∗
CE(I) 8 −102.3  ±  3.5 −106.0  ±  3.6NS <0.05 −77.6  ±  2.8 −78.0  ±  2.4NS <0.05
CE + Ca2+ 10 −102.3  ±  2.4 +21.1  ±  4.5∗ −77.5  ±  0.9 −66.4  ±  1.8∗
CE(I) + Ca2+ 8 −102.5  ±  3.3 −99.2  ±  2.5NS <0.05 −78.5  ±  1.6 −78.8  ±  1.7NS <0.05
CE + Ca2+ (BZA) 7 −99.8  ±  2.3 +23.4  ±  3.7∗ >0.05† −78.9  ±  1.2 −67.2  ±  2.0∗ >0.05†
Anti-CE 8 −100.4  ±  3.1 −121.9  ±  5.2∗ −79.5  ±  0.9 −84.6  ±  2.2∗
Anti-CE(I) 7 −98.9  ±  2.9 −100.9  ±  3.1NS <0.05 −79.2  ±  1.2 −79.6  ±  1.8NS <0.05

(I), heat-inactivated form; BZA, bath benzolamide. ∗, Significant difference (P < 0.05) as compared with pretreatments. NS, no significant difference (P > 0.05) as compared with pretreatments. P indicates the significance of tests between the two groups; †, as compared with CE + Ca2+ group. Control values were obtained approximately 5 min before, while the test values were observed about 30 min after the application of the proteins.